SCHEMBL3318037

SCHEMBL3318037

CCC(CC)C(N)c1ccnn1S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
LMNA P02545 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2C19 P33261 3/20 0.43
CYP1A2 P05177 2/20 0.43
NPSR1 Q6W5P4 3/20 0.42
MAPT P10636 2/20 0.42
MCOLN3 Q8TDD5 2/20 0.42
GAA P10253 2/20 0.42
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
SLC9A1 P19634 1/20 0.37
RAPGEF4 Q8WZA2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3318176 0.84 ALDH1A1 (0.43) ALDH1A1LMNASMN1; SMN2L3MBTL1CYP2C9
SCHEMBL3834062 0.77 ALDH1A1 (0.37) ALDH1A1LMNASMN1; SMN2L3MBTL1CYP2C9
SCHEMBL3834065 0.73 HTT (0.42) ALDH1A1LMNASMN1; SMN2CYP2C9CYP2C19
SCHEMBL3317874 0.72 PSEN1 (0.60) ALDH1A1LMNASMN1; SMN2L3MBTL1CYP2C9
SCHEMBL4024005 0.69 MAPT (0.47) ALDH1A1LMNAL3MBTL1NPSR1MAPT
SCHEMBL5055437 0.67 MAPT (0.45) ALDH1A1LMNANPSR1MAPTMCOLN3
SCHEMBL3466100 0.65 MEN1 (0.44) ALDH1A1LMNASMN1; SMN2MAPTGAA
SCHEMBL5591195 0.63 ALDH1A1 (0.41) ALDH1A1LMNASMN1; SMN2L3MBTL1NPSR1
SCHEMBL568616 0.62 PKM (0.46) ALDH1A1LMNASMN1; SMN2CYP2C9CYP2C19
SCHEMBL567741 0.62 LMNA (0.39) ALDH1A1LMNASMN1; SMN2L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole WYETH LLP (US) 2010-06-10 US disclosed
US-7674813-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2010-03-09 US disclosed
EP-1709003-B1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH CORP (US) 2009-09-23 EP disclosed
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2008-10-09 US disclosed
US-7399778-B2 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole WYETH (US) 2008-07-15 US disclosed
EP-1709003-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE Wyeth (US) 2006-10-11 EP disclosed
WO-2005073198-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE WYETH (US) 2005-08-11 WO disclosed
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole WYETH (US) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144812-A1 Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production Containing an Azole APP, IAPP, PARK7 ALDH1A1 4118/4885LMNA 2937/4885SMN1; SMN2 971/4885
US-20080249150-A1 HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION CONTAINING AN AZOLE APP, IAPP, PARK7 ALDH1A1 4118/4885LMNA 2937/4885SMN1; SMN2 971/4885
US-20050171180-A1 Heterocyclic sulfonamide inhibtors of beta amyloid production containing an azole IAPP, APP, CBR3 ALDH1A1 3920/4885LMNA 2624/4885SMN1; SMN2 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.